Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus rating of “Buy” by the eight ...
Leerink Partners analyst David Risinger maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) on January 16. The company’s ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) hit a new 52-week low on Friday .The company traded as low as $12.37 and last traded at $12.60, with a volume of 297315 shares trading ...
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of ...
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ...
Oruka Therapeutics (ORKA) announced that it is expected to be added to the Nasdaq Biotechnology Index (NBI). Oruka’s addition will become effective prior to market open on Monday, December 23rd ...
Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life ...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback